PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Evaluation of HVHF for the treatment of severe acute pancreatitis accompanying MODS.

Abstract Systemic inflammatory response syndrome (SIRS) prevention is key to severe acute pancreatitis (SAP) treatment and the assessment of high-volume hemofiltration (HVHF) for treating SAP accompanying multiple organ dysfunction syndromes.In this prospective controlled study, 40 SAP patients were divided into 2 groups: control (n = 22, treated with fasting, decompression, and intravenous somatostatin) and HVHF (n = 18, HVHF administration in addition to the treatment in the control group) groups; and were assessed for serum and urine amylase, WBC, C-reactive protein (CRP), and hepatic and renal functions. Vital signs and abdominal symptoms were recorded, and complications and mortality were analyzed.APACHE II scores in the HVHF group were significantly lower than in the control group at 3 and 7 days (6.3 ± 1.7 vs 9.2 ± 2.1 and 3.3 ± 0.8 vs 6.2 ± 1.7, respectively). Compared with controls, serum, and urine amylase, WBC, CRP, and organ functions significantly improved after HVHF treatment. Meanwhile, mortality (16.7% vs 31.8%) and complication (11.1% vs 40.9%) rates were significantly reduced.The other clinical parameters were significantly ameliorated by HVHF. HVHF rapidly reduces abdominal symptoms and improves prognosis, reducing mortality in SAP patients; and is likely through systemic inflammatory response syndrome attenuation in the early disease stage.
PMID
Related Publications

Study the effects of high-volume hemofiltration and fluid resuscitation on removing blood lactic acid and pro-inflammatory cytokines in patients with refractory septic shock.

Effects of continuous high-volume hemofiltration on experimental severe acute pancreatitis in pigs.

Short-term continuous high-volume hemofiltration on clinical outcomes of severe acute pancreatitis.

High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study.

Clinical effects of continuous high volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29505517
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20180309
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 1
DP  - 2018 Jan
TI  - Evaluation of HVHF for the treatment of severe acute pancreatitis accompanying
      MODS.
PG  - e9417
LID - 10.1097/MD.0000000000009417 [doi]
AB  - Systemic inflammatory response syndrome (SIRS) prevention is key to severe acute 
      pancreatitis (SAP) treatment and the assessment of high-volume hemofiltration
      (HVHF) for treating SAP accompanying multiple organ dysfunction syndromes.In this
      prospective controlled study, 40 SAP patients were divided into 2 groups: control
      (n = 22, treated with fasting, decompression, and intravenous somatostatin) and
      HVHF (n = 18, HVHF administration in addition to the treatment in the control
      group) groups; and were assessed for serum and urine amylase, WBC, C-reactive
      protein (CRP), and hepatic and renal functions. Vital signs and abdominal
      symptoms were recorded, and complications and mortality were analyzed.APACHE II
      scores in the HVHF group were significantly lower than in the control group at 3 
      and 7 days (6.3 +/- 1.7 vs 9.2 +/- 2.1 and 3.3 +/- 0.8 vs 6.2 +/- 1.7,
      respectively). Compared with controls, serum, and urine amylase, WBC, CRP, and
      organ functions significantly improved after HVHF treatment. Meanwhile, mortality
      (16.7% vs 31.8%) and complication (11.1% vs 40.9%) rates were significantly
      reduced.The other clinical parameters were significantly ameliorated by HVHF.
      HVHF rapidly reduces abdominal symptoms and improves prognosis, reducing
      mortality in SAP patients; and is likely through systemic inflammatory response
      syndrome attenuation in the early disease stage.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Abulimiti, Alimujiang
AU  - Abulimiti A
AD  - Department of General Surgery, First Affiliated Hospital of Xinjiang Medical
      University, Urimqi, China.
FAU - Husaiyin, Aierhati
AU  - Husaiyin A
FAU - Sailai, Yalikun
AU  - Sailai Y
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.2.1.- (Amylases)
SB  - AIM
SB  - IM
MH  - APACHE
MH  - Adult
MH  - Aged
MH  - Amylases/blood/urine
MH  - Blood Urea Nitrogen
MH  - C-Reactive Protein/metabolism
MH  - Female
MH  - Hemofiltration/*statistics & numerical data
MH  - Humans
MH  - Leukocyte Count
MH  - Liver Function Tests
MH  - Male
MH  - Middle Aged
MH  - Multiple Organ Failure/blood/*etiology/urine
MH  - Pancreatitis/blood/complications/*therapy/urine
MH  - Prospective Studies
EDAT- 2018/03/06 06:00
MHDA- 2018/03/10 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
AID - 10.1097/MD.0000000000009417 [doi]
AID - 00005792-201801050-00014 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jan;97(1):e9417. doi: 10.1097/MD.0000000000009417.